Mallinckrodt Pharmaceuticals filed for US bankruptcy yesterday, putting the brakes on several ongoing suits accusing the company of monopolizing the infantile spasm drug Acthar.In a release, Mallinckrodt said it “voluntarily initiated Chapter 11 proceedings in the U.S. Bankruptcy Court for the District of Delaware to modify its capital structure, including restructuring portions of